Nearly every GLP-1 drug on the market today, semaglutide, tirzepatide, liraglutide, is given by injection, and that's not an arbitrary manufacturing choice. It reflects a basic pharmacological obstacle that any oral peptide drug has to solve, and different drugs have solved it in very different ways.

Why Peptides Don't Survive Being Swallowed

Peptides are chains of amino acids, and the digestive system is, functionally, a machine built to break chains of amino acids apart. Stomach acid and digestive enzymes like pepsin and trypsin degrade peptides before they can be absorbed intact, and even peptides that survive digestion struggle to cross the intestinal wall into the bloodstream in meaningful amounts. This is why insulin, another peptide hormone, is injected rather than taken as a pill, and it's the same reason injectable GLP-1 drugs are formulated the way they are.

How Oral Semaglutide Works Around the Problem

Oral semaglutide, marketed as Rybelsus, is still a peptide, and it addresses digestive breakdown by being co-formulated with an absorption enhancer called SNAC, which temporarily raises local stomach pH and helps a small fraction of the dose cross the stomach lining before it's degraded. Because this absorption window is narrow and inefficient, the drug's labeling requires taking it on an empty stomach with no more than four ounces of plain water, then waiting at least 30 minutes before eating, drinking anything else, or taking other oral medications. Even with those precautions, oral semaglutide's bioavailability is low, which is part of why its approved doses are so much higher than the injectable version's.

Orforglipron's Different Approach

Orforglipron, approved in 2026 and covered in more detail elsewhere on this site, takes a fundamentally different path: it isn't a peptide at all. It's a small, non-peptide molecule engineered from the ground up to activate the GLP-1 receptor while being chemically stable enough to survive the digestive tract without an absorption-enhancing workaround. That's the structural reason its FDA labeling doesn't require fasting, a specific water amount, or a post-dose waiting period, and why it can be taken at any time of day. It's a different kind of molecule solving the same biological problem in a different way, rather than a peptide drug with a better delivery trick.

Comparing the Practical Tradeoffs

Injectable GLP-1 drugs generally deliver a more predictable, consistent dose since they bypass digestion entirely, and once-weekly injectable dosing has an adherence advantage for people who dislike remembering strict daily meal-timing rules. Oral semaglutide offers needle-free dosing but layers on real administration constraints. Orforglipron offers needle-free dosing without those constraints, but as with any newer drug, it has a shorter track record of real-world use than injectable options that have been prescribed for years. Reported side effects across all three, primarily nausea, constipation, diarrhea, and vomiting, are broadly similar, since they stem from the same GLP-1 receptor activity rather than the route of administration.

The Bottom Line

The oral-versus-injectable question in GLP-1 therapy isn't just about needle aversion, it's a genuine pharmacology problem, and the two current oral approaches solve it in opposite ways: one works around peptide fragility with an absorption enhancer and strict rules, the other avoids the fragility altogether by not being a peptide. Which option makes sense for a given patient depends on medical history, other medications, lifestyle, and cost and insurance coverage, all of which are worth discussing directly with a prescribing physician.